MTOR and prostate carcinoma: Many studies have established dysregulation of the PI3K/AKT/mTOR pathway in tumors, and mainly in the biologic regulation of the breast cancer (Mohan et al., 2016), gastric cancer (Samuels, Wang et al., 2004), liver cancer (Grabinski et al., 2012), colorectal cancer (Francipane et al., 2014) and prostate cancer (Chang et al., 2015).